Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy 10x Genomics stock

Own 10x Genomics stock in just a few minutes.

10x Genomics, Inc is a health information services business based in the US. 10x Genomics shares (TXG) are listed on the NASDAQ and all prices are listed in US Dollars. 10x Genomics employs 852 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in 10x Genomics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TXG – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

10x Genomics share price

Use our graph to track the performance of TXG stocks over time.

10x Genomics shares at a glance

Information last updated 2021-04-21.
52-week range$72.04 - $203.20
50-day moving average $175.17
200-day moving average $162.11
Wall St. target price$209.57
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-7.27

Buy 10x Genomics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy 10x Genomics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is 10x Genomics under- or over-valued?

Valuing 10x Genomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of 10x Genomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

10x Genomics's EBITDA

10x Genomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.1 million.

The EBITDA is a measure of a 10x Genomics's overall financial performance and is widely used to measure a its profitability.

10x Genomics financials

Revenue TTM $298.8 million
Gross profit TTM $249.9 million
Return on assets TTM -5.96%
Return on equity TTM -93.64%
Profit margin -181.61%
Book value $4.39
Market capitalisation $20.3 billion

TTM: trailing 12 months

Shorting 10x Genomics shares

There are currently 1.8 million 10x Genomics shares held short by investors – that's known as 10x Genomics's "short interest". This figure is 48.2% up from 1.2 million last month.

There are a few different ways that this level of interest in shorting 10x Genomics shares can be evaluated.

10x Genomics's "short interest ratio" (SIR)

10x Genomics's "short interest ratio" (SIR) is the quantity of 10x Genomics shares currently shorted divided by the average quantity of 10x Genomics shares traded daily (recently around 837910.79812207). 10x Genomics's SIR currently stands at 2.13. In other words for every 100,000 10x Genomics shares traded daily on the market, roughly 2130 shares are currently held short.

However 10x Genomics's short interest can also be evaluated against the total number of 10x Genomics shares, or, against the total number of tradable 10x Genomics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case 10x Genomics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 10x Genomics shares in existence, roughly 20 shares are currently held short) or 0.0212% of the tradable shares (for every 100,000 tradable 10x Genomics shares, roughly 21 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against 10x Genomics.

Find out more about how you can short 10x Genomics stock.

10x Genomics share dividends

We're not expecting 10x Genomics to pay a dividend over the next 12 months.

Have 10x Genomics's shares ever split?

10x Genomics's shares were split on a 1:2 basis on 16 July 2006. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 10x Genomics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for 10x Genomics shares which in turn could have impacted 10x Genomics's share price.

10x Genomics overview

10x Genomics, Inc. , a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site